The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor mutational burden, PD-1, negative Wnt/ß-catenin regulators, and positive MHC class II antigen presentation regulators as predictors of longer survival after immune checkpoint inhibitors across cancers: A comprehensive analysis of 400 immunity biomarkers.
 
Yu Fujiwara
Travel, Accommodations, Expenses - Conquer Cancer, the ASCO Foundation
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Daisuke Nishizaki
No Relationships to Disclose
 
Hirotaka Miyashita
No Relationships to Disclose
 
Suzanna Lee
No Relationships to Disclose
 
Mary Nesline
Employment - LabCorp
Stock and Other Ownership Interests - LabCorp
Patents, Royalties, Other Intellectual Property - Predictive signature assay (Inst)
 
Jeffrey Conroy
Employment - LabCorp
Stock and Other Ownership Interests - LabCorp
Patents, Royalties, Other Intellectual Property - LabCorp (Inst)
 
Paul DePietro
Employment - LabCorp
Stock and Other Ownership Interests - LabCorp
 
Sarabjot Pabla
Employment - LabCorp
Stock and Other Ownership Interests - LabCorp
Patents, Royalties, Other Intellectual Property - LabCorp (Inst)
 
Sadakatsu Ikeda
Honoraria - ACT Genomics; ACT Med; AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical; Canon Medical System; Chugai Pharma; Guardant Health; MSD; Novartis; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Illumina
Research Funding - ACT Genomics (Inst); Canon Medical System (Inst); Hitachi (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix; XZOM
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EMD Serono; EOM Pharmaceuticals; Gaido; Iylon; Jackson Laboratory for Genomic Medicine; LabCorp; Lanauria Therapeutics; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Precirix; Precirix; Prosperdtx; Quanta Therapeutics; Recordati; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Sysmex (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation